Gracell

Gracell Biotechnologies is a global, clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficient cell and gene therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is advancing a robust pipeline of autologous and allogeneic therapeutic candidates in clinical development for cancer and autoimmune diseases. These products hold the promise of addressing persistent major industry challenges associated with traditional CAR-T therapies, including prolonged manufacturing timelines, suboptimal product cell quality, high treatment costs, and lack of efficacy against solid tumors.